Buprenorphine and Naltrexone for Opioid Use Disorder - FAME Session
- Non-Member - Free!
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
Buprenorphine and Naltrexone for Opioid Use Disorder
This webinar will provide an overview of medication treatment of OUD. The webinar also covers the resources within the context of the COVID-19 pandemic and how it may impact the way that you decide on medications for opioid use disorder.
This session was recorded as part of the ASAM Fundamentals of Addiction Medicine ECHO (FAME) sessions. The participation in the live FAME sessions will provide CME but viewing this on-demand recording will not provide CME. To attend upcoming live FAME sessions (eligible for CME) please sign up on the website: https://www.asam.org/education/live-online-cme/fundamentals-program/fame-teleecho.
By completing this webinar, you will be able to:
- Interact with patients and professional colleagues so as to display professionalism in all activities, by demonstrating commitment to the health and well-being of individuals and society through ethical practice, profession-led regulation, and high personal standards of behavior.
- Identify their feelings and attitudes that promote or prevent therapeutic responses to their patients with substance use disorders.
- Understand the addictive disorders as developmental biopsychosocial disorders.
- Take an evidence-based approach to detecting substance use disorders.
- Respond to positive substance use screening results with brief counseling strategies, appropriate to the patient’s readiness to change.
- Use motivational interviewing with patients ambivalent about changing their substance use behavior.
- Conduct a biopsychosocial and developmental ambulatory assessment of an adult with a suspected SUD to match the patient to an appropriate level of care.
- List the indications, contraindications and duration of treatment of evidence based pharmacotherapy for alcohol, tobacco, and opioid use disorders and refer patient to specialty care where appropriate.
- Reflect on the role of behavioral interventions for patients and families including formal intensive ambulatory and inpatient treatment and informal programs such as mutual aid groups in the recovery process for patients in their practice/ communities.
Original Recording Information
Date: Friday, April 24, 2020
Time: 11:00 am - 1:00 pm (ET)
- Miriam Komaromy, MD
MD, FACP, DFASAM
Miriam Komaromy, MD, FACP, DFASAM is an internal medicine and addiction specialist physician and is the Medical Director of the Grayken Center for Addiction at Boston Medical Center, and a faculty member in the Section of General Internal Medicine, Boston University, in the United States. Dr. Komaromy is a member of the board of directors of the American Society of Addiction Medicine. She is vice-chair of ASAM’s national medical education committee, and she chairs their Fundamentals of addiction medicine committee. She was elected ASAM educator of the year for 2019. She was an Associate Director in the ECHO Institute in New Mexico 2014-2019, and led the development of ECHO programs that are focused on treatment of substance use disorders, behavioral health disorders, and care of complex populations for the past 14 years. She has served as Medical Director for New Mexico’s addiction treatment hospital, and led the development of the state’s guidelines for treatment of opioid use disorder. Dr. Komaromy lectures nationally and internationally on addiction medicine topics and care of complex populations. In 2018-2019, Dr. Komaromy served as a Fulbright Scholar in Hanoi, Vietnam, performing research and providing education on treatment of substance use disorders,